ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME
20190276525 ยท 2019-09-12
Assignee
Inventors
Cpc classification
C07K2317/24
CHEMISTRY; METALLURGY
C07K2317/76
CHEMISTRY; METALLURGY
A61P29/00
HUMAN NECESSITIES
C07K16/22
CHEMISTRY; METALLURGY
C07K16/467
CHEMISTRY; METALLURGY
A61P35/00
HUMAN NECESSITIES
International classification
Abstract
A method of preparing an antibody suitable for use in an equine is provided. Also provided are equinised antibodies which specifically bind to equine neuronal growth factor (NGF) and neutralise the ability of equine NGF to bind to the p75 or TrkA equine NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in an equine using said antibodies and/or nucleic acids.
Claims
1-5. (canceled)
6. A neutralizing antibody or an antigen binding fragment thereof which is capable of specifically binding to equine nerve growth factor (NGF) wherein the antibody or antibody binding fragment comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1 or an amino acid sequence which has an identity of at least 85% thereto and/or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence which has an identity of at least 85% thereto.
7. The antibody or antigen binding fragment thereof as claimed in claim 6 wherein the antibody is a chimeric antibody or an equinised antibody.
8. The antibody or antigen binding fragment thereof as claimed in claim 6 wherein the heavy chain constant domains are selected or modified by way of amino acid substitution or deletion such that said constant domains do not mediate downstream effector functions.
9. The antibody or antigen binding fragment thereof as claimed in claim 8 wherein the heavy chain is of the equine isotype HC2 or HC6.
10. The antibody or antigen binding fragment thereof as claimed in claim 9 wherein the heavy chain is of the equine isotype HC2.
11. The antibody or antigen binding fragment thereof as claimed in claim 6 wherein the light chain comprises the amino acid sequence of SEQ ID NO:4, or an amino acid sequence which has an identity of at least 85% thereto.
12. The antibody or antigen binding fragment thereof as claimed claim 6 wherein the heavy chain comprises the amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9, or an amino acid sequence which has a sequence identity of at least 85% thereto.
13. The antibody or antigen binding fragment thereof as claimed in claim 12 wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:6, or an amino acid sequence which has a sequence identity of at least 85% thereto.
14. An anti-equine NGF antibody, or equine NGF binding fragment thereof, the antibody or antibody binding fragment comprising a light chain variable region comprising at least one of: an FR1 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:10; an FR2 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:11; an FR3 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:12; and an FR4 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:13; and/or a heavy chain variable region comprising at least one of: an FR1 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:14; an FR2 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:15; an FR3 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:16; and an FR4 framework region consisting or comprising of the amino acid sequence of SEQ ID NO:17;
15. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a light chain variable domain having an FR1 region of SEQ ID NO:10 which has been modified by one or more of the amino acid substitutions selected from the group consisting of V, S7 is T, A9 is E, L11 is V, S12 is T or A, A13 is V, S14 is T, E17 is Q, T18 is R, T20 is E, 121 is I, L, M or V and E22 is K.
16. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a light chain variable domain having an FR1 region of SEQ ID NO:10 which has been modified by one or more of the amino acid substitutions selected from the group consisting of D1 is G, K or V; I2 is F, N, S or T; V3 is A, G, I or M; M4 is L, Q or V; T5 is A or I; S7 is F; A9 is D, P or S, S10 is F, L or T; L11 is S; S12 is E or V; A13 is L, Q or T; S14 is A or P; L15 is P or R; G16 is R; T18 is S, G or K; V19 is A; T20 is D or V; I21 is T; and E22 is L, N, Q, R, S or T.
17. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a light chain variable domain having the FR2 region of SEQ ID NO:11 which has been modified by one or more of the amino acid substitutions selected from the group consisting of K5 is R; Q8 is E; S9 is A; K11 is R or E; and L12 is R.
18. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a light chain variable domain having the FR2 region of SEQ ID NO:11 which has been modified by one or more of the amino acid substitutions selected from the group consisting of Y2 is F or H; Q3 is R or S; Q4 is H, K, R or V; K5 is V, P6 is I, L or S; S9 is P, R, V or T; P10 is L; K11 is I or L; L12 is A, E, G, H, Q, or W; L13 is F, I, M or V; 114 is F, T, M or V; and Y15 is A, C, D, E, F, G, H, Q, R, S, T or V.
19. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a light chain variable domain having the FR3 region of SEQ ID NO:12 which has been modified by one or more of the amino acid substitutions selected from the group consisting of S4 is D; F6 is Y; 014 is E; Y15 is F; S16 is T; N20 is S; S24 is A; S29 is I, S or T; and F31 is Y.
20. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a light chain variable domain having the FR3 region of SEQ ID NO:12 which has been modified by one or more of the amino acid substitutions selected from the group consisting of G1 is D or F; V2 is A or F; P3 is L or S; S4 is A, E, G or L; F6 is L; S7 is C, F, G, N, R or T; G8 is A; S9 is D, E, G, K, R, T or W; G10 is A, R or V; S11 is A, F, T or Y; G12 is E or T; T13 is A, S or W; S16 is A or V; L17 is F or P; T18 is A, I, S or V; I19 is V;, N20 is D, G or T; S21 is D, E, P, R or T; Q23 is E or R; S24 is E or T; E25 is A, D, G or T; D26 is N, V27 is A, L, E, G or S, A28 is G, S29 is D, E, F, L, M, N or V, Y30 is C and F31 is H, S, T, V or W.
21. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a light chain variable domain having the FR4 region of SEQ ID NO:13 which has been modified by the amino acid substitution L9 is I.
22. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a light chain variable domain having the FR4 region of SEQ ID NO:13 which has been modified by one or more of the amino acid substitutions selected from the group consisting of F1 is I or L; Q3 is L; T5 is S; K6 is M; N or R; L7 is M or V; E8 is A; D or K; L9 is F, M or V: and K10 is A, E, G, I, Q, R, T or V.
23. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a heavy chain variable domain having the FR1 region of SEQ ID NO:14 which has been modified by the amino acid substitution N13 is K.
24. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a heavy chain variable domain having the FR1 region of SEQ ID NO:14 which has been modified by one or more of the amino acid substitutions selected from the group consisting of K5 is Q; G10 is D; L11 is Q; V12 is M; N13 is M or R; P14 is I or S; S15 is A or G; Q16 is E; T17 is A; S19 is T; T21 is S or V; T23 is A, F or S; V24 is I; S25 is T; G26 is A; F27 is A, G, I, M, N Q or S; S28 is D, H, I, L, N or P; L29 is D; S, T or V; and T30 is E, I, N or R.
25. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a heavy chain variable domain having the FR2 region of SEQ ID NO:15 which has been modified by the amino acid substitution W12 is F.
26. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a heavy chain variable domain having the FR2 region of SEQ ID NO:15 which has been modified by one or more of the amino acid substitutions selected from the group consisting of V2 is L; A5 is P, S or V; KS is W; G9 is R; L10 is P or W; W12 is E, H, R, V or Y; and G14 is A, D or S.
27. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a heavy chain variable domain having the FR3 region of SEQ ID NO:16 which has been modified by one or more of the amino acid substitutions selected from the group consisting of T3 is S; R6 is K; F14 is Y; Q16 is T; M17 is L; and R32 is G.
28. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a heavy chain variable domain having the FR3 region of SEQ ID NO:16 which has been modified by one or more of the amino acid substitutions selected from the group consisting of A2 can be C, G, I, T or V; T3 can be D, I, M N or R; I4 is V, T5 is I; L or S; R6 is E or S; D7 is E or N; T8 is A, E, I, P, S or Y; S9 is E, G, K or T; K10 is E, L, N, Q or R; S11 is G, K, N or R; Q12 is E, H or R; V13 is A, I, L, F or S; F14 is L, R, S, T or V; L15 is V; Q16 is I; M17 is V; N18 is D, K, R, S or T; S19 is D, E, G, K, M or T; L20 is M or V; T21 is S; S22 is D, E, G or R; E23 is D or G; T25 is A; A26 is S; V27 is D; Y29 is A, F, I or W; A31 is E, G, I, S, T or V; and R32 is A, E, G, H, I, K or S.
29. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 which comprises a heavy chain variable domain having the FR4 region of SEQ ID NO:17 which has been modified by the amino acid substitution Q3 is P.
30. The anti-equine NGF antibody or equine NGF binding fragment as claimed in claim 14 wherein the heavy chain is of the equine isotype HC2.
31. (canceled)
32. An antibody or binding fragment thereof which specifically binds to one or more equine soluble proteins wherein the antibody does not mediate downstream effector functions and wherein the antibody is purifiable by binding to Protein A.
33. The antibody or binding fragment as claimed in claim 32 wherein the antibody comprises a heavy chain having an equine HC2 isotype.
34. The antibody or binding fragment as claimed in claim 32 wherein the one or more soluble proteins is selected from the group consisting of CSF, interleukins, growth factors and neurotrophins.
35. The antibody or binding fragment as claimed in claim 34 wherein the one or more soluble proteins is NGF.
36. The antibody or binding fragment as claimed in either one of claim 6 or 14 which specifically binds to equine NGF with a binding affinity having an equilibrium dissociation constant (KD) of 1108 or less.
37. The antibody or binding fragment as claimed in either one of claim 6 or 14 wherein binding of the antibody or fragment to equine NGF inhibits the ability of equine NGF to bind to the p75 or the TrkA equine NGF receptors.
38. The antibody or binding fragment as claimed in either one of claim 6 or 14 wherein the antibody or binding fragment is not immunogenic in equines.
39. The antibody or binding fragment as claimed in either one of claim 6 or 14 wherein the antigen binding fragment is selected from the group consisting of a single chain Fv (scFv) antibody fragment, a Fab antibody fragment, a Fab antibody fragment and a F(ab)2 antibody fragment.
40. (canceled)
41. The antibody or binding fragment as claimed in either one of claim 6 or 14 wherein the antibody is a chimeric antibody or an equinised antibody.
42. A method for treating, inhibiting or ameliorating pain in an equine, the method comprising the steps of: providing a therapeutically effective amount of an anti-equine NGF antibody, or antigen binding fragment thereof, wherein the antibody is an equinised antibody, and administering the same to an equine in need thereof.
43. The method as claimed in claim 42 wherein the anti-equine NGF antibody is an antibody as claimed in either one of claim 6 or 14.
44-45. (canceled)
46. The method as claimed in claim 42 wherein the pain is selected from the group consisting of neuropathic pain, inflammatory pain, pruritic pain, peri-operative pain, post-operative pain and post-surgical pain.
47. The method as claimed in claim 46 wherein the post-operative pain is selected from the group consisting of orthopaedic surgery and soft tissue surgery.
48-69. (canceled)
70. A pharmaceutical composition for treating pain or a condition resulting in or caused by pain in an equine, comprising a therapeutically effective amount of an anti-equine NGF equinised antibody or binding fragment thereof according to either one of claim 6 or 14 along with at least one pharmaceutically acceptable carrier, excipient or diluent.
71.-97. (canceled)
Description
BRIEF DESCRIPTION OF THE FIGURES
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
[0099]
[0100]
[0101]
[0102]
[0103]
DETAILED DESCRIPTION OF THE INVENTION
[0104] Following extensive experimentation, the inventor has taken the rat anti-mouse NGF monoclonal antibody (MAb) aD11 amino acid sequence and used this to produce a non-immunogenic anti-NGF antibody. The resulting antibody, which may be a chimeric or equinised antibody, is not produced using standard CDR grafting techniques and is surprisingly shown to exhibit high affinity binding to equine NGF. Even more surprisingly, the antibody is shown to neutralise equine NGF biological function, most specifically by inhibiting the binding of NGF to cell-based receptors TrkA and p75. Furthermore, it has also been discovered, unexpectedly, that when administered to an equine, neutralising antibodies are not produced there against. Accordingly, the non-immunogenic antibody of the invention is suitable for long term relief of chronic pain in horses.
[0105] The process of generating the heavy and light chain variable domains for the antibodies of the invention which has been employed by the inventor results in the replacement of specific rat (donor) amino acid residues which are present within the framework regions of the light and heavy chain variable domains with residues which, based on the inventor's analysis, will retain the conformation of the CDR regions and therefore maintain binding specificity and avidity, while reducing the presence of immunogenic epitopes which may result in neutralising antibodies being generated against the antibody, if it were to be administered to equines in an unaltered form. Specifically, the method of preparing antibodies of the invention (known as PETisation) comprises assessing the sequence of the framework regions of a donor (e.g. rat) antibody for suitability for administering to an equine by comparing the sequence of the framework regions of the donor antibody with the sequence of an antibody or a pool of antibodies derived from equines. Although the comparison may be between the donor sequence and a single member of the target sequence, it will be obvious that comparison with a pool of target sequences is preferred because this will expand the number of natural options at each Kabat position in the target species. Not only will this increase the chance of a match between the donor and the target, but it will also expand the options for replacement where a match does not exist. As a result, a replacement with characteristics as close as possible to the donor will be able to be chosen. Where the donor sequence and the equine sequence differ at any Kabat number or corresponding position, the donor sequence is modified to substitute the amino acid residue in question with an amino acid residue which is known to be natural at that position in equines.
[0106] Where substitution of an amino acid residue present in a donor immunoglobulin framework region is required, typically this is undertaken using the principle of conservative substitution wherein an amino acid residue is replaced with an amino acid residue which is natural at that Kabat position in an equine and is as closely related as possible in size, charge and hydrophobicity to the amino acid being substituted in the donor sequence. The intention is to choose a replacement which would cause no, or at least only minimum, perturbation or disruption to the three-dimensional structure of the donor antibody. In certain situations, there will be no clear option and each choice will have benefits and downsides. A final decision may require three-dimensional modelling or even expression of various alternative sequences. However, generally, a clear preference will be available. As a result of this procedure, a change in the donor sequence is only made when that residue would be foreign in the target and the replacement amino acid is as closely related as possible to that which it replaces. Thus, the creation of foreign epitopes is avoided, but the overall three-dimensional structure is preserved and as a result, affinity and specificity are also preserved.
[0107] The light and heavy chain constant regions are typically derived from equine (target) derived antibodies. The heavy chain constant domains are selected or modified such that they do not mediate downstream effector functions. As it has been found, quite surprisingly, that no or minimal neutralising antibodies are produced against the antibodies produced according to the invention, the antibodies have surprisingly been found to have the associated benefit of long circulatory half-life and the option for repeat dosing. Furthermore, as the substitution of the framework residues is performed in such a manner that it does not affect the three-dimensional conformation of the CDR regions, there will be no variation in binding specificity.
[0108] While hybrid murine-equine chimeric antibodies are known, there are currently no examples of fully equinised monoclonal antibodies described in the literature. Accordingly, it is highly unexpected that such an antibody can be produced and shown to have therapeutic utility. There are four major IgG isotypes in man and mouse and while nomenclature is similar they differ in behaviour and function including affinity for bacterial products such as Protein A and Protein G, their ability to activate the complement dependent cytolysis (CDC) and their ability to induce killing of target cells through antibody dependent cellular cytotoxity (ADCC). The selection of IgG isotypes with CDC and ADCC active or armed constant domains is of clinical benefit when antibodies are designed to eliminate target cells bearing their cognate antigen, such as in oncology or infection control (e.g. in human medical use human IgG1 isotypes are preferred for the above purposes). By contrast, the activation of the immune system is considered undesirable in other settings such as in the relief of inflammation, pain or autoimmunity and so human IgG isotypes with minimal CDC and ADCC activity are preferred (e.g. in such human medical use, IgG4 isotypes are often preferred). Seven distinct immunoglobulin gamma (IgG) heavy chain constant domain isotypes have been described in the equine immune system along with single kappa and lambda constant domain sequences.
[0109] The seven equine heavy chain constant domains IgG1, IgG2, IgG3, IgG4, IgG5, IgG6 and IgG7 have been characterised in terms of functional activity mediated thereby. The selection of IgG isotypes with CDC and ADCC active constant domains is considered to be of benefit when antibodies are designed to eliminate target cells bearing the cognate antigen, such as in oncology or infection control, e.g. in human medical use human IgG1 isotypes are preferred. By contrast, the activation of the immune system is considered undesirable in other settings such as in the relief of inflammation, pain or autoimmunity and so human IgG isotypes with minimal or disarmed CDC and ADCC activity are preferred, e.g. in human medical use, IgG4 isotypes would be selected. Equine MAb isotypes have a broader spectrum of activities and so the selection of armed or disarmed heavy chains is presumed to be of similar value.
[0110] The antibodies of the invention comprise equine derived heavy and light chain constant domains. Furthermore, the complementarity determining regions are derived from the rat aD11 anti-mouse NGF antibody. The aD11 antibody was first described by Cattaneo et al. (Cattaneo A, Rapposelli B, Calissano P. (1988) Three distinct types of monoclonal antibodies after long-term immunization of rats with mouse nerve growth factor. J Neurochem 50(4):1003-1010). The alphaD11 antibody was subsequently cloned by Ruberti et al. (Ruberti, F. et al. (1993) Cloning and Expression of an Anti-Nerve Growth Factor (NGF) Antibody for Studies Using the Neuroantibody Approach. Cellular and Molecular Neurobiology. 13(5):559-568). The CDR regions derived from the aD11 antibody are combined with framework region sequences which have been determined by the inventor to preserve CDR tertiary structure, and therefore binding specificity, while preventing neutralising antibodies being raised there against, when the antibody is administered to an equine. Each of the light and heavy chain variable regions contains four framework regions, referred to as FR1-FR4. For each of these framework regions, the inventor has identified a preferred amino residue (a so called preferred residue) for each specific position, and furthermore alternative amino acid residues which could also be provided at that position. Tables 1 to 8 below illustrate the 4 framework regions for each of the heavy and light chains. The tables provide the amino acid position relative to that specific framework region and further according to the Kabat numbering system used to identify the position of a particular residue along the length of the complete heavy or light chain variable domain. The residue or residues shown as group 1 residues are the preferred residues, while the group 2 residues are alternative residues. However, these would generally not be preferable to the residues shown in group 1 relating to that specific position. The amino acid residues are identified using the single letter nomenclature system.
TABLE-US-00001 TABLE1 LightchainvariabledomainFR1residues Light Kabat Group1 Group2 chain light amino amino FR1 chain acid acid position numbering residues residues 1 1 D GKV 2 2 IV FNST 3 3 V AGIM 4 4 M LQV 5 5 T AI 6 6 Q 7 7 ST F 8 8 P 9 9 AE DPS 10 10 S FLT 11 11 LV S 12 12 STA EV 13 13 AV LQT 14 14 ST AP
TABLE-US-00002 TABLE2 LightchainvariabledomainFR2residues Light Kabat Group1 Group2 chain light amino amino FR2 chain acid acid position numbering residues residues 1 35 W Y 2 36 Y FH 3 37 Q RS 4 38 Q HKRV 5 39 KR V 6 40 P ILS 7 41 G 8 42 QE 9 43 AS PRVT 10 44 P L 11 45 KRE IL 12 46 LR AEGHQW 13 47 L FIMV 14 48 I FTMV 15 49 Y ACDEFG HQRSTV
TABLE-US-00003 TABLE3 LightchainvariabledomainFR3residues Light Kabat Group1 Group2 chain light amino amino FR3 chain acid acid position numbering residues residues 1 57 G DF 2 58 V AF 3 59 p LS 4 60 SD AEGL 5 61 R 6 62 FY L 7 63 S CFGNRT 8 64 G A 9 65 S DEGKRTW 10 66 G ARV 11 67 S AFTY 12 68 G ET 13 69 T ASW 14 70 DE 15 71 YF 16 72 ST AV 17 73 L FP 18 74 T AISV 19 75 I V 20 76 NS DGT 21 77 S DEPRT 22 78 L 23 79 Q ER 24 80 AS ET 25 81 E ADGT 26 82 D N 27 82A V ALEGS 28 82B A G 29 82C IST DEFLMNV 30 83 Y C 31 84 FY HSTVW 32 85 C
TABLE-US-00004 TABLE4 LightchainvariabledomainFR4residues Light Kabat Group1 Group2 chain light amino amino FR4 chain acid acid position numbering residues residues 1 95 F IL 2 96 G 3 97 Q L 4 98 G 5 99 T S 6 100 K MNR 7 101 L MV 8 102 E ADK 9 103 IL FMV 10 104 K AEGIQRTV
TABLE-US-00005 TABLE5 HeavychainvariabledomainFR1residues Heavy Kabat Group1 Group2 chain heavy amino amino FR1 chain acid acid position numbering residues residues 1 1 Q 2 2 V 3 3 Q 4 4 L 5 5 K Q 6 6 E 7 7 s 8 8 G 9 9 p 10 10 G D 11 11 L Q 12 12 V M 13 13 NK MR 14 14 P IS 15 15 s AG 16 16 Q E 17 17 T A 18 18 L 19 19 s T 20 20 L 21 21 T SV 22 22 C 23 23 T AFS 24 24 V I 25 25 S T 26 26 G A 27 27 FL AGIMNQS 28 28 S DHILNP 29 29 L DSTV 30 30 TS EINR
TABLE-US-00006 TABLE6 HeavychainvariabledomainFR2residues Heavy Kabat Group1 Group2 Chain heavy Amino Amino FR2 chain Acid Acid position numbering residues residues 1 36 W 2 37 V L 3 38 R 4 39 Q 5 40 A PSV 6 41 p 7 42 G 8 43 K w 9 44 G R 10 45 L PW 11 46 E 12 47 WF EHRVY 13 48 V 14 49 G ADS
TABLE-US-00007 TABLE7 HeavychainvariabledomainFR3residues Heavy Kabat Group1 Group2 chain heavy amino amino FR3 chain acid acid position numbering residues residues 1 66 R 2 67 A CGITV 3 68 ST DIMNR 4 69 I V 5 70 T ILS 6 71 RK ES 7 72 D EN 8 73 T AEIPSY 9 74 S EGKT 10 75 K ELNQR 11 76 S GKNR 12 77 Q EHR 13 78 V AILFS 14 79 FY LRSTV 15 80 L V 16 81 QT I 17 82 ML V 18 82A N DKRST 19 82B s DEGKMT 20 82C L MV 21 83 T s 22 84 s DEGR 23 85 E DG 24 86 D 25 87 T A 26 88 A s 27 89 V D 28 90 y 29 91 y AFIW 30 92 C 31 93 A EGISTV 32 94 RG AEGHIKS
TABLE-US-00008 TABLE 8 Heavy chain variable domain FR4 residues Heavy Kabat heavy Group 1 Group 2 Chain FR4 chain Amino Amino Add position numbering Acid residues residues 1 103 W 2 104 G 3 105 Q p 4 106 G 5 107 I 6 108 L 7 109 V 8 110 T 9 111 V 10 112 s 11 113
[0111] The equinised antibody of the invention therefore differs from, for example, a chimeric monoclonal antibody which consists of a complete variable region derived from a first species and constant domains derived from a second species, or from a CDR-grafted equinised antibody, where the complementarity determining regions (CDRs) of the heavy and light chain variable regions comprise amino acid residues derived from a donor antibody and introduced into framework regions (FR) and constant regions (CR) derived from a target antibody or from equine germline sequences.
[0112] It is preferred that the equinised antibody substantially retains the binding properties of the parent (donor) antibody from which the CDRs are derived. That means that the equinised antibody will exhibit the same or substantially the same antigen-binding affinity and avidity as the donor antibody from which the CDRs are derived. Ideally, the affinity of the equinised antibody will not be less than 10% of the donor antibody affinity for the target epitope, more preferably not less than about 30%, and most preferably the affinity will not be less than 50% of the parent (donor) antibody. Methods for assaying antigen-binding affinity are well known in the art and include half-maximal binding assays, competition assays, and Scatchard analysis.
[0113] As defined hereinbefore, the present invention extends to binding members or antigen binding fragments derived from the equinised antibodies of the invention. Such antigen binding fragments refer to one or more fragments of an antibody that retain the ability to specifically bind to equine NGF. It has been shown that the antigen binding function of an antibody can be performed by fragments of a full-length antibody. In certain embodiments, the binding members or antigen binding fragments may be isolated binding members. A binding member or antigen binding fragment of the invention may comprise a fragment of the antibodies of the present invention, e.g. a fragment of a fully equinised antibody molecule, such as the heavy or light chain only, or, for example, the variable domain of the heavy and/or light chain. In certain embodiments, a binding member may typically comprise, consist, or consist essentially of an antibody VH and/or VL domain. VH domains of binding members are also provided as part of the invention. Within each of the VH and VL domains are 3 complementarity determining regions (CDRs), along with 4 associated framework regions (FRs). A VH domain typically comprises 3 HCDRs (heavy chain complementarity determining regions), and a VL domain typically comprises 3 LCDRs (light chain complementarity regions). Accordingly, a binding member may comprise a VH domain comprising, in sequence, VH CDR1 (or HCDR1), CDR2 (HCDR2) and CDR3 (HCDR3) regions along with a plurality of associated framework regions. A binding member may additionally or alternatively comprise a VL domain comprising VL CDR1, CDR2 and CDR3 domains along with associated framework regions. The VH or VL domains typically comprise four framework regions, FR1, FR2, FR3 and FR4, interspersed with the 3 complementarity determining regions in the following arrangement: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0114]
[0115] In
[0116]
[0117] As described herein before, an antibody binding fragment may be selected from the group comprising, but not limited to, a Fab fragment, a Fab fragment and an scFv (single chain variable fragment), or from a peptidomimetic, a diabody, or a related multivalent derivative.
[0118] In certain embodiments the antibody binding fragment is a Fab or F(ab)2 fragment, which consists of the VL, VH, CL and CH1 domains of a heterotetrameric antibody. In certain embodiments, the VL domain has an amino acid sequence of SEQ ID NO:1 and the VH domain has an amino acid sequence of SEQ ID NO:2. In certain embodiments, the CL and CH1 domains are based on the amino acid sequence of a CL and CH1 domain of an equine immunoglobulin, in particular an IgG2 (HC2) or IgG6(HC6) equine derived constant domain.
[0119] Techniques used for the recombinant production of Fab, Fab and F(ab)2 fragments are well known to the person skilled in the art and include those disclosed in International PCT Patent Publication WO 92/22324, and in Sawai et al., Direct Production of the Fab Fragment Derived From the Sperm Immobilizing Antibody Using Polymerase Chain Reaction and cDNA Expression Vectors, 1995, AJRI 34:26-34. Examples of techniques which can be used to produce scFv (single chain Fv fragments) are disclosed in Huston et al., Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins, Methods in Enzymology, vol. 203:46-88 (1991), the contents of which are incorporated by reference.
[0120] In certain embodiments, antibody fragments can be derived from full length antibodies by proteolytic digestion according to the method of Morimoto (Morimoto et al., Single-step purification of F(ab)2 fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSK gel Phenyl-5PW Journal of Biochemical and Biophysical Methods 24:107-117 (1992)). Antibody fragments can also be produced directly by host cells (Carter et al., High level Escherichia coli expression and production of a bivalent humanized antibody fragment Bio/Technology 10:163-167 (1992)).
[0121] In addition to providing an equinised monoclonal antibody which has binding specificity to equine NGF and which antagonises equine NGF function, the present invention further extends to binding members other than antibodies comprising a pair of binding domains based on the amino acid sequence of a VL (light chain variable) region as defined in SEQ ID NO:1 and an amino acid sequence of a VH (heavy chain variable) region as defined in SEQ ID NO:2. In particular, the invention extends to single binding domains which are based on either the VL or VH region of the equinised antibodies of the antibodies of the invention.
[0122] Accordingly, in certain further embodiments of the present invention, there is provided a binding member comprising, consisting or consisting essentially of a single binding domain derived from the humanised antibody of the invention. In certain embodiments, the single binding domain is derived from the amino acid sequence of the VH (heavy chain variable domain) as defined in SEQ ID NO:2 or SEQ ID NO:4. Such a binding domain may be used as a targeting agent to equine NGF.
[0123] In certain embodiments, further engineering techniques can be used to modify the antibodies of the present invention, for example by including modifications of the Fe region which can alter serum half-life, complement fixation, Fe receptor binding and/or antigen dependent cellular cytotoxicity. Further, in certain embodiments, antibodies or antibody fragments can be produced which have altered glycosylation patterns. In certain embodiments, an antibody of the invention is altered to increase or decrease the extent to which the antibody is glycosylated. Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except praline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. The inventor has provided aglycosylated equine constant domains, these being defined herein as SEQ ID NO:8 or SEQ ID NO:9.
[0124] In certain further embodiments, the anti-equine NGF antibodies of the invention can be PEGylated by reacting the antibody with a polyethylene glycol (PEG) derivative. In certain embodiments, the antibody is defucosylated and therefore lacks fucose residues.
[0125] In certain embodiments, modifications in the biological properties of an antibody may be accomplished by selecting substitutions that affect (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Amino acids may be grouped according to similarities in the properties of their side chains (A. L. Lehninger, in Biochemistry, 2nd Ed., 73-75, Worth Publishers, New York (1975)): (1) non-polar: Ala (A), Val (V), Leu (L), Iie (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gin (Q); (3) acidic: Asp (D), Glu (E); (4) basic: Lys (K), Arg (R), His (H). Alternatively, naturally occurring residues may be divided into groups based on common side-chain properties: (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Iie; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gin; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe. Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, into the remaining (e.g. non-conserved) sites.
[0126] In various further aspects, the present invention extends to an immunoconjugate comprising an anti-equine NGF antibody of the invention, or an antigen binding portion thereof linked to a partner molecule. In certain embodiments, such an antibody-partner molecule conjugate is conjugated by means of a chemical linker, such as a peptidyl linker, a hydrazine linker or a disulphide linker. In certain embodiments, the coupling partner is an effector molecule, label, drug, or carrier molecule. Suitable techniques for coupling the antibodies of the invention to both peptidyl and non-peptidyl coupling partners will be well known to persons skilled in the art. Examples of suitable labels include detectable labels, such as a radiolabel, or an enzymatic label, such as horse radish peroxidase, or chemical moieties, such as biotin. Alternatively, the label may be a functional label, for example, ricin, or pro-drugs which are capable of converting prodrugs into active drugs at the site of antibody binding.
[0127] In various further aspects, the present invention extends to polynucleotides, and in particular isolated polynucleotides, which encode the equinised antibodies, antibody fragments and binding members of the present invention. As defined herein, a polynucleotide includes any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA, or modified RNA or DNA, including without limitation, single and double stranded RNA, and RNA which is a mixture of single and double stranded regions. A polynucleotide of the invention, e.g. a polynucleotide which encodes a polypeptide or polypeptides of the invention includes allelic variants thereof and/or their complements including a polynucleotide that hybridises to such nucleotide sequences under conditions of moderate or high stringency.
[0128] The present invention further extends to antibody mimetics, such as domain antibodies, nanobodies, unibodies, versabodies, and duocalins which are based on the equine NGF antibodies of the present invention. A wide variety of antibody mimetic technologies are known to the person skilled in the art. For example, so called, domain antibodies (Domantis, UK) are small functional binding units of antibodies which correspond to the variable regions of either the light or heavy chains of human antibodies. Directions for the production of such domain antibodies can be found in U.S. Pat. Nos. 6,291,158, 6,582,915 and 6,593,081. Nanobodies are antibody-derived therapeutic proteins which contain unique structural and functional properties of naturally occurring heavy chain antibodies found in camelids. Unibodies are a further antibody fragment technology, based upon the removal of the hinge region of IgG4 antibodies. The deletion of the hinge region results in a molecule which is approximately half the size of a traditional IgG4 antibody and which has a univalent binding region. Unibodies preserve the property of IgG4 antibodies of being inert and therefore not inducing immune responses. Further binding molecules include affibody molecules (U.S. Pat. No. 5,831,012), DARPins (designed ankyrin repeat proteins) (International PCT Patent Application Publication WO 02/20565) and anticalins (U.S. Pat. No. 7,250,297 and WO 99/16873). Verabodies are a further antibody mimetic technology. Versabodies (Amunix, US Patent Application Publication No. 2007i0191272) are small proteins, referred to as microproteins, of 3-5 kDa with greater than 15% cysteine residues, which form a high disulphide bond density scaffold which replaces the hydrophobic core. Avimers are another type of antibody mimetic. Avimers originate from the recombination of families of human serum proteins. They are single protein chains composed of modular binding domains, each of which is designed to bind to a particular target site. The avimers can bind simultaneously to sites on a single protein target and/or sites on multiple protein targets. Known as multi-point attachment or avidity, this binding mechanism mimics the way cells and molecules interact in the body, supports the generation of antagonists and agonists, and results in drugs with multiple functions and potent activity. Avimers libraries can be produced according to WO 2004/044011 incorporated herein by reference and for example US 2005/0053973. Avimers libraries are also available commercially from Avidia Inc, Mountain View, Calif., USA.
Antibody Production
[0129] The antibodies and binding members of the invention may be produced wholly or partly by chemical synthesis. For example, the antibodies and binding members of the invention can be prepared by techniques which are well known to the person skilled in the art, such as standard liquid peptide synthesis, or by solid-phase peptide synthesis methods. Alternatively, the antibodies and binding members may be prepared in solution using liquid phase peptide synthesis techniques, or further by a combination of solid-phase, liquid phase and solution chemistry. The present invention further extends to the production of the antibodies or binding members of the invention by expression of a nucleic acid which encodes at least one amino acid which comprises an antibody of the invention in a suitable expression system, such that a desired peptide or polypeptide can be encoded. For example, a nucleic acid encoding the amino acid light chain and a second nucleic acid encoding an amino acid heavy chain can be expressed to provide an antibody of the present invention. Accordingly, in certain further aspects of the invention, there is provided nucleic acids encoding amino acid sequences which form the antibodies or binding members of the present invention.
[0130] Typically, nucleic acids encoding the amino acid sequences which form antibodies or binding members of the present invention can be provided in an isolated or purified form or provided in a form which is substantially free of material which can be naturally associated with it, with the exception of one or more regulatory sequences. Nucleic acid which expresses an antibody or binding member of the invention may be wholly or partially synthetic and may include, but is not limited to DNA, cDNA and RNA. Nucleic acid sequences encoding the antibodies or binding members of the invention can be readily prepared by the skilled person using techniques which are well known to those skilled in the art, such as those described in Sambrook et al. Molecular Cloning, A laboratory manual, cold Spring Harbor Laboratory Press, Volumes 1-3, 2001 (ISBN-0879695773), and Ausubel et al. Short Protocols in Molecular Biology. John Wiley and Sons, 4th Edition, 1999 (ISBN-0471250929). Said techniques include (i) the use of the polymerase chain reaction (PCR) to amplify samples of nucleic acid, (ii) chemical synthesis, or (iii) preparation of cDNA sequences. DNA encoding antibodies or binding members of the invention may be generated and used in any suitable way known to those skilled in the art, including taking encoding DNA, identifying suitable restriction enzyme recognition sites either side of the portion to be expressed, and cutting out said portion from the DNA. The excised portion may then be operably linked to a suitable promoter and expressed in a suitable expression system, such as a commercially available expression system. Alternatively, the relevant portions of DNA can be amplified by using suitable PCR primers. Modifications to the DNA sequences can be made by using site directed mutagenesis. Nucleic acid sequences encoding the antibodies or binding members of the invention may be provided as constructs in the form of a plasmid, vector, transcription or expression cassette which comprises at least one nucleic acid as described above. The construct may be comprised within a recombinant host cell which comprises one or more constructs as above. Expression may conveniently be achieved by culturing, under appropriate conditions, recombinant host cells containing suitable nucleic acid sequences. Following expression, the antibody or antibody fragments may be isolated and/or purified using any suitable technique, then used as appropriate.
[0131] Systems for cloning and expression of a polypeptide in a variety of different host cells are well known. Suitable host cells include bacteria, mammalian cells, yeast, insect and baculovirus systems. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary (CHO) cells, Hela cells, baby hamster kidney cells and NSO mouse myeloma cells. A common, preferred bacterial host is E. coli. The expression of antibodies and antibody fragments in prokaryotic cells such as E. coli is well established in the art. Expression in eukaryotic cells in culture is also available to those skilled in the art as an option for production of a binding member. General techniques for the production of antibodies are well known to the person skilled in the field, with such methods being discussed in, for example, Kohler and Milstein (1975) Nature 256: 495-497; U.S. Pat. No. 4,376,110; Harlow and Lane, Antibodies: A Laboratory Manual, (1988) Cold Spring Harbor. Techniques for the preparation of recombinant antibody molecules are described in the above references and also in, for example, European Patent Number 0,368,684.
[0132] In certain embodiments of the invention, recombinant nucleic acids comprising an insert coding for a heavy chain variable domain and/or for a light chain variable domain of antibodies or binding members are employed. By definition, such nucleic acids comprise encode single stranded nucleic acids, double stranded nucleic acids consisting of said coding nucleic acids and of complementary nucleic acids thereto, or these complementary (single stranded) nucleic acids themselves. Furthermore, nucleic acids encoding a heavy chain variable domain, and/or a light chain variable domain of antibodies can be enzymatically or chemically synthesised nucleic acids having the authentic sequence coding for a naturally occurring heavy chain variable domain and/or for the light chain variable domain, or a mutant thereof.
[0133] An antibody of the invention may be produced by recombinant means, not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which is preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. The heterologous signal sequence selected preferably is one that is recognized and processed (i.e., cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process a native antibody signal sequence, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II leaders.
[0134] The term isolated, when used in reference to the equinised antibodies of the invention, or to binding members derived therefrom, or polypeptides which encode the same, refers to the state in which said antibodies, binding members or nucleic acids (polynucleotides) are provided in an isolated and/or purified form, that is they have been separated, isolated or purified from their natural environment, and are provided in a substantially pure or homogeneous form, or, in the case of nucleic acid, free or substantially free of nucleic acid or genes of origin other than the sequence encoding a polypeptide with the required function. Accordingly, such isolated antibodies, binding members and isolated nucleic acids will be free or substantially free of material with which they are naturally associated, such as other polypeptides or nucleic acids with which they are found in their natural environment, or the environment in which they are prepared (e.g. cell culture) when such preparation is by recombinant DNA technology practised in vitro or in vivo.
[0135] Antibodies, binding members and nucleic acids may be formulated with diluents or adjuvants and still, for practical purposes, be considered as being provided in an isolated form. For example, the antibodies and binding members can be mixed with gelatin or other carriers if used to coat microtiter plates for use in immunoassays or will be mixed with pharmaceutically acceptable carriers or diluents when used in diagnosis or therapy. The antibodies or binding members may be glycosylated, either naturally or by systems of heterologous eukaryotic cells (e.g. CHO or NSO cells, or they may be (for example if produced by expression in a prokaryotic cell) unglycosylated (aglycosylated).
[0136] Heterogeneous preparations comprising anti-equine NGF equinised antibody molecules also form part of the invention. For example, such preparations may be mixtures of antibodies with full-length heavy chains and heavy chains lacking the C-terminal lysine, with various degrees of glycosylation and/or with derivatized amino acids, such as cyclization of an N-terminal glutamic acid to form a pyroglutamic acid residue.
Pharmaceutical Compositions
[0137] Typically, the pharmaceutical compositions of the invention are formulated in a liquid formulation, a lyophilized formulation, a lyophilized formulation that is reconstituted as a liquid, or as an aerosol formulation. In certain embodiments, the antibody in the formulation is at a concentration of: about 0.5 mg/ml to about 250 mg/ml, about 0.5 mg/ml to about 45 mg/ml, about 0.5 mg/ml to about 100 mg/ml, about 100 mg/ml to about 200 mg/ml, or about 50 mg/ml to about 250 mg/ml.
[0138] In certain embodiments, the formulation further comprises a buffer. Typically, the pH of the formulation is from about pH 5.5 to about pH 6.5. In certain embodiments, the buffer may comprise from about 4 mM to about 60 mM histidine buffer, about 5 mM to about 25 mM succinate buffer, or about 5 mM to 25 mM acetate buffer. In certain embodiments, the buffer comprises sodium chloride at a concentration of from about 10 mM to 300 mM, typically at around 125 mM concentration and sodium citrate at a concentration of from about 5 mM to 50 mM, typically 25 mM. In certain embodiments the formulation can further comprise a surfactant at a concentration of just above 0% to about 0.2%. In certain embodiments the surfactant is selected from the group consisting of, but not limited to: polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-65, polysorbate-80, polysorbate-85, and combinations thereof. In a preferred embodiment, the surfactant is polysorbate-20 and may further comprise sodium chloride at a concentration of about 125 mM and sodium citrate at a concentration of about 25 mM.
Administration
[0139] The antibodies or binding members of the present invention may be administered alone but will preferably be administered as a pharmaceutical composition which will generally comprise a suitable pharmaceutically acceptable excipient, diluent or carrier selected depending on the intended route of administration. Examples of suitable pharmaceutical carriers include; water, glycerol, ethanol and the like.
[0140] The monoclonal antibody or binding member of the present invention may be administered to an equine patient in need of treatment via any suitable route. Typically, the composition can be administered parenterally by injection or infusion. Examples of preferred routes for parenteral administration include, but are not limited to; intravenous, intracardial, intraarterial, intraperitoneal, intramuscular, intracavity, subcutaneous, transmucosal, inhalation or transdermal. Routes of administration may further include topical and enteral, for example, mucosal (including pulmonary), oral, nasal, rectal. In embodiments where the composition is delivered as an injectable composition, for example in intravenous, intradermal or subcutaneous application, the active ingredient can be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as sodium chloride injection, Ringer's injection or, Lactated Ringer's injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required. The composition may also be administered via microspheres, liposomes, other microparticulate delivery systems or sustained release formulations placed in certain tissues including blood.
[0141] Examples of the techniques and protocols mentioned above and other techniques and protocols which may be used in accordance with the invention can be found in Remington's Pharmaceutical Sciences, 18th edition, Gennaro, A. R., Lippincott Williams & Wilkins; 20th edition ISBN 0-912734-04-3 and Pharmaceutical Dosage Forms and Drug Delivery Systems; Ansel, H. C. et al. 7th Edition ISBN 0-683305-72-7, the entire disclosures of which is herein incorporated by reference.
[0142] The antibodies and compositions of the invention are typically administered to a subject in a therapeutically effective amount, this being an amount sufficient to show benefit to the subject to whom the composition is administered. The actual dose administered, and rate and time-course of administration, will depend on, and can be determined with due reference to, the nature and severity of the condition which is being treated, as well as factors such as the age, sex and weight of the subject being treated, as well as the route of administration. Further due consideration should be given to the properties of the composition, for example, its binding activity and in-vivo plasma life, the concentration of the antibody or binding member in the formulation, as well as the route, site and rate of delivery. Dosage regimens can include a single administration of the antibody or composition of the invention, or multiple administrative doses of the antibody or composition. The antibody or antibody containing compositions can further be administered sequentially or separately with other therapeutics and medicaments which are used for the treatment of the condition for which the antibody or binding member of the present invention is being administered to treat. Examples of dosage regimens which can be administered to a subject can be selected from the group comprising, but not limited to; 1 g/kg/day through to 20 mg/kg/day, 1 g/kg/day through to 10 mg/kg/day, 10 g/kg/day through to 1 mg/kg/day. In certain embodiments, the dosage will be such that a plasma concentration of from 1 g/ml to 100 g/ml of the antibody is obtained. However, the actual dose of the composition administered, and rate and time-course of administration, will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g. decisions on dosage etc., is ultimately within the responsibility and at the discretion of veterinary practitioners and other veterinary doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners.
Definitions
[0143] Unless otherwise defined, all technical and scientific terms used herein have the meaning commonly understood by a person who is skilled in the art in the field of the present invention. The meaning and scope of the terms should be clear, however, in the event of any ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition.
[0144] Throughout the specification, unless the context demands otherwise, the terms comprise or include, or variations such as comprises or comprising, includes or including will be understood to imply the inclusion of a stated integer or group of integers, but not the exclusion of any other integer or group of integers.
[0145] As used herein, terms such as a, an and the include singular and plural referents unless the context clearly demands otherwise. Thus, for example, reference to an active agent or a pharmacologically active agent includes a single active agent as well as two or more different active agents in combination, while references to a carrier includes mixtures of two or more carriers as well as a single carrier, and the like. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
[0146] As herein defined, the term pain means an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. In relation to operative or post-operative pain, the US Animal Welfare Act (Animal Welfare Act 2002. AWA regulations, CFR, Title 9 (Animals and Animal Products), Chapter 1 (Animal and Plant Health Inspection Service, Department of Agriculture). Subchapter A (Animal Welfare), Parts 1-4) defines a painful procedure as any procedure that would reasonably be expected to cause more than slight or momentary pain or distress in a human being to which that procedure was applied, that is, pain in excess of that caused by injections or other minor procedures. Therefore, if an equine undergoes a painful surgical procedure, the animal should receive postoperative analgesics. In further instance, an equine may be experiencing significant or chronic pain as a result of an associated medical condition such as an arthritic, for example polyarthritis, rheumatoid arthritis, inflammation, pruritis, osteoarthritis or a cancerous or malignant condition.
[0147] The term nociception refers to the perception of noxious stimuli. As herein defined neuropathic pain (also known as neuralgia) is a pain that comes from problems with signals from the nerves. It may arise as a consequence of a lesion or disease affecting the somatosensory system. There are causes of neuropathic pain and it may be associated with abnormal sensations called dysesthesia, which occur spontaneously. Alternatively, it may be associated with allodynia which results when the pain comes on, or gets worse, with a touch or stimulus that would not normally cause pain. For example, a slight touch on the face may trigger pain if you have trigeminal neuralgia, or the pressure of the bedclothes may trigger pain if you have diabetic neuropathy. Neuropathic pain may also result from allodynia, where the pain comes on, or gets worse, with a touch or stimulus that would not normally cause pain. For example, a slight touch to the face may trigger pain if a subject has trigeminal neuralgia. Neuropathic pain relating to hyperalgesia means that severe pain results from a stimulus or touch that would normally cause only slight discomfort, while paresthesia means that uncomfortable or painful feelings occur even when there is nothing in contact with the area causing the pain, for example pins and needles. Other forms of neuropathic pain involve pruritis or itch which can be associated with allergic or inflammatory responses in the skin and inflammatory pain resulting from tissue damage and repair processes.
[0148] As defined herein, the term NGF neutralising antibody or similar describes an antibody that is capable of neutralising the biological activation and signaling of NGF. The neutralising antibody, which may also be referred to as an antagonistic antibody, or a blocking antibody, specifically and preferably selectively, binds to NGF and inhibits one or more biological activities of NGF. For example, the neutralising antibody may inhibit the binding of a NGF to its target ligand, such as the cell membrane bound TrkA or p75 receptors.
[0149] As used herein, the term biological activity refers to any one or more inherent biological properties of a molecule (whether present naturally as found in vivo or provided or enabled by recombinant means). Biological properties include but are not limited to receptor binding and/or activation; induction of cell signaling or cell proliferation, inhibiting cell growth, induction of cytokine production, induction of apoptosis, and enzymatic activity.
[0150] The term complementarity determining region (CDR), as used herein, refers to amino acid sequences which together define the binding affinity and specificity of the natural Fv region of a native immunoglobulin binding site as delineated by Kabat et al. (Kabat, E. A., Wu, T. T., Perry, H., Gottesman, K. and Foeller, C. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition. NIH Publication No. 91-3242). The term framework region (FR), as used herein, refers to amino acid sequences interposed between CDRs. These portions of the antibody serve to hold the CDRs in appropriate orientation (allows for CDRs to bind antigen).
[0151] The term constant region (CR) as used herein, refers to the portion of the antibody molecule which confers effector functions. In the present invention, constant regions typically mean equine constant regions, that is that the constant regions of the subject equinised antibodies are derived from equine immunoglobulins. The heavy chain constant region can be selected from any equine heavy chain isotype.
[0152] The term chimeric antibody as used herein refers to an antibody containing sequences derived from two different antibodies, which typically are of different species. Most typically chimeric antibodies comprise variable domains derived from a donor specifies which bind specifically to a target epitope and constant domains derived from antibodies obtained from the target species to whom the antibody is to be administered.
[0153] The term immunogenicity as used herein refers to a measure of the ability of a targeting protein or therapeutic moiety to elicit an immune response (humoral or cellular) when administered to a recipient. The present invention is concerned with the immunogenicity of the subject equinised antibodies. Preferably the antibodies of the present invention have no immunogenicity, that is that no neutralizing antibodies will be raised against them when administered to an equine, and further, no effector functions are mediated by the Fe regions of the antibody.
[0154] The term identity or sequence identity as used herein, means that at any particular amino acid residue position in an aligned sequence, the amino acid residue is identical between the aligned sequences. The term similarity or sequence similarity as used herein, indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. For example, leucine may be substituted for an isoleucine or valine residue. This may be referred to as conservative substitution. Preferably when the amino acid sequences of the invention are modified by way of conservative substitution of any of the amino acid residues contained therein, these changes have no effect on the binding specificity or functional activity of the resulting antibody when compared to the unmodified antibody. Sequence identity with respect to a (native) polypeptide of the invention and its functional derivative relates to the percentage of amino acid residues in the candidate sequence which are identical with the residues of the corresponding native polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percentage homology, and not considering any conservative substitutions as part of the sequence identity. Neither N- or C-terminal extensions, nor insertions shall be construed as reducing sequence identity or homology. Methods and computer programs for performing an alignment of two or more amino acid sequences and determining their sequence identity or homology are well known to the person skilled in the art. For example, the percentage of identity or similarity of 2 amino acid sequences can be readily calculated using algorithms e.g. BLAST (Altschul et al. 1990), FASTA (Pearson & Lipman 1988), or the Smith-Waterman algorithm (Smith & Waterman 1981).
[0155] As used herein, reference to an amino acid residue having the highest homology to a second amino acid residue refers to the amino acid residue which has the most characteristics or properties in common with the second amino acid residue. In determining whether an amino acid residue has the highest homology to a second amino acid residue, an assessment may typically be made of factors such as, but not limited to, charge, polarity, hydrophobicity, side arm mass and side arm dimension.
[0156] The term corresponding position as used herein to refer to an amino acid residue that is present in a second sequence at a position corresponding to a specified amino acid residue in a first sequence is intended to refer to the position in the second sequence which is the same position as the position in the first sequence when the two sequences are aligned to allow for maximum sequence identity between the two sequences. Amino acid residues at corresponding positions have the same Kabat numbering.
[0157] The term consists essentially of or consisting essentially of as used herein means that a polypeptide may have additional features or elements beyond those described provided that such additional features or elements do not materially affect the ability of the antibody or antibody fragment to have binding specificity to equine NGF. That is, the antibody or antibody fragments comprising the polypeptides may have additional features or elements that do not interfere with the ability of the antibody or antibody fragments to bind to equine NGF and antagonise equine NGF functional activity. Such modifications may be introduced into the amino acid sequence in order to reduce the immunogenicity of the antibody. For example, a polypeptide consisting essentially of a specified sequence may contain one, two, three, four, five or more additional, deleted or substituted amino acids, at either end or at both ends of the sequence provided that these amino acids do not interfere with, inhibit, block or interrupt the role of the antibody or fragment in binding to equine NGF and sequestering its biological function. Similarly, a polypeptide molecule which contributes to the equine NGF antagonistic antibodies of the invention may be chemically modified with one or more functional groups provided that such functional groups do not interfere with the ability of the antibody or antibody fragment to bind to equine NGF and antagonise its function.
[0158] As used herein, the term effective amount or therapeutically effective amount means the amount of an agent, binding compound, small molecule, fusion protein or peptidomimetic of the invention which is required to suppress equine NGF binding to the p75 and/or TrkA receptors.
[0159] The terms polypeptide, peptide, or protein are used interchangeably herein to designate a linear series of amino acid residues connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues. The amino acid residues are usually in the natural L isomeric form. However, residues in the D isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide.
[0160] As herein defined an antibody encompasses antigen-binding proteins which specifically bind to a target antigen of interest, in this case equine nerve growth factor, having one or more polypeptides that can be recombinantly prepared or which are genetically encodable by immunoglobulin genes, or fragments of immunoglobulin genes. The term antibody encompasses monoclonal and chimeric antibodies, in particular equinised antibodies, and further encompasses polyclonal antibodies or antibodies of any class or subtype. An antibody further extends to hybrid antibodies, bispecific antibodies, heteroantibodies and to functional fragments thereof which retain antigen binding.
[0161] The phrase specifically binds to refers to the binding of an antibody to a specific protein or target which is present amongst a heterogeneous population of proteins. Hence, when present in specific immunoassay conditions, the antibodies bind to a particular protein, in this case equine NGF, and do not bind in a significant amount to other proteins present in the sample.
[0162] As defined herein, an equine may also be referred to as a horse. Equines belong to the subspecies with the trinomial name Equus ferus caballus, these being hooved (ungulate) mammals. Equines are a subspecies of the family Equidae and include any species classified therein and extends to the over 300 breeds of horse known. The present invention will now be described with reference to the following examples which are provided for the purpose of illustration and are not intended to be construed as being limiting on the present invention.
EXAMPLES
Example 1
Production of Antibodies
[0163] Whole antibody sequences were produced by combining equinised light chain and heavy chain variable domains of SEQ ID NO:1 and SEQ ID NO:2, respectively to C-terminal equine constant heavy chain or constant light chain domains. The equinised aD11 VH domain was combined with two different equine heavy chain constant domains; HC2 (IgG2) and HC6 (IgG6) and the equinised aD11 VL domain with the equine kappa light chain constant domain. The sequences of the full-length mature antibody chains are shown in SEQ ID 4 (light chain with kappa constant domain) and 6 (heavy chain with HC2 constant domain). The combined amino acid sequences were converted to expressible form in mammalian cells by the optimal selection of codons and full chemical gene synthesis and cloning into a mammalian cell expression vector pcDNA3.1+. The resultant cDNAs were transfected into CHO cells and the supernatants analysed as detailed in Examples 2 to 5.
Example 2
Determining Binding of Antibodies to Murine and Equine NGF
[0164] Equinised heavy and light chain cDNAs were transfected into CHO cells, the supernatants harvested and reacted in ELISA format with either equine or murine NGF. Following incubation and wash steps, the bound equine antibody was detected by reactivity with a goat-anti equine IgG specific polyclonal antibody linked to horseradish peroxidase (HRP) and developed using TMB. The optical density of the resulting product was measured at 450 nm and compared with that from mock empty vector transfected supernatant (denoted as Mock in
[0165] The results are shown in the graph of
Example 3
Purification of Equinised Antibodies
[0166] The supernatants obtained from Example 2 were purified using a Protein A column, separated by SOS-PAGE and tested for reactivity to anti-equine IgG polyclonal antibody HRP. The SOS-PAGE gel was also stained using Coomassie blue to detect heavy and light chains. The anti-equine IgG polyclonal antibody preparation predominantly recognises the equine heavy chains. The results are shown in
Example 4
Inhibition of NGF Induced Proliferation of TF-1 Cells by Equinised Antibodies
[0167] Serial dilutions of CHO cell transfectant supernatants from Example 2 (antagonist) were incubated with TF-1 cells in the presence of 1.0 ng/ml NGF. The resultant proliferation was measured by thymidine incorporation. The results are shown in
Example 5
Complement Deposition Induced by Antigen-Captured Equinised Antibodies
[0168] Protein A purified transfectant supernatants from Example 2 were incubated with plates coated with 0.1 ng/ml NGF to capture the antibodies. The plates were washed and coated with 0.1 ng/ml NGF to capture the antibodies. The plates were washed and then incubated with human serum and bound complement C1q was measured by binding of anti-human C1q polyclonal antibody HRP and developed as above. The binding of C1q to antigen-captured eqN-HC2+eqN-kLC-1 was compared to a human anti-NGF MAb with human IgG1 Fe domain as positive control and an IgG4 variant as negative control.
Complement Binding Method:
[0169] Plates were coated with 100 l/well of 5 g/ml mouse NGF and blocked with 5% BSNPBS. Coated wells were incubated for 1 hour at room temperature with cell culture supernatants, containing recombinant equine anti-NGF IgG, diluted in PBS/1% BSA (100 l/well). The plates were washed and incubated for 1 hour at room temperature with 100 l/well of human serum diluted 1/100 in veronal buffered saline containing 0.5 mM MgCl2, 2 mM CaCl2, 0.05% Tween-20, 0.1% gelatin and 0.5% BSA. After washing, plates were incubated with 100 l of a 1/800 dilution of sheep anti-C1q-HRP (Serotec) in PBS/1% BSA. After washing, plates were developed by the addition of 100 l TMB substrate (Thermo Scientific). Development was stopped by the addition of 100 l of 2N H2SO4 and absorbance read at 450 nm. The results are shown in the graph of
[0170] Accordingly, it is demonstrated herein, quite surprisingly, that where an antibody of the invention has an equine derived heavy chain of the HC2 (IgG2 equine heavy chain constant domain subtype), the binding of the antibody to equine NGF does not result in complement activation or other downstream effector functions, such as ADCC. Hence, said antibodies, in antagonising the biological functional activity of equine NGF by preventing binding of equine NGF to the membrane bound TrkA or p75 receptors, inhibit the associated downstream intracellular signaling cascade. Furthermore, as NGF expression frequently occurs in the proximity of nerves and the like, the NGF antagonising or neutralising antibodies of the invention, which have equine derived heavy chain of the HC2 (IgG2) subtype, can sequester equine NGF biological activity without recruiting a wider immune response. Such functional properties are unexpected, yet highly desirable.
Example 6
Preferential Purification of Equine IgG Isotype HC2 but not HC6, Using Protein A Affinity Chromatography
[0171] CHO cell supernatants resulting from transfection of the HC2 and HC6 variants of equinised aD11 were loaded onto a Protein A affinity column (as per
Example 7
Anti-Equine NGF Monoclonal AntibodiesSafety and Pyrexia
[0172] Anti-equine NGF monoclonal antibodies of this invention are expressed in CHO cells and purified by a combination of Protein A chromatography and/or size exclusion chromatography and are buffer exchanged into phosphate buffered saline. The antibodies are injected intravenously into horses at 0.01-10 mg/kg body weight and assessed for signs of toxicity by visual inspection by a veterinarian, change in body weight, body temperature and plasma biochemistry. No changes are expected to be observed in these or any plasma biochemistry analytes.
Example 8
Plasma Pharmacokinetics of Anti-Equine NGF Monoclonal Antibodies In VivoSerum Half-Life and Immunogenicity
[0173] The anti-equine NGF monoclonal antibodies of this invention are expressed in CHO cells and purified by a combination of Protein A chromatography and/or size exclusion chromatography and buffer exchanged into phosphate buffered saline. The antibodies are injected intravenously into horses in the range 0.01-10 mg/kg body weight and plasma samples are taken at various times over the next 2 weeks. Diluted plasma samples are assessed for anti-equine NGF antibody concentration by ELISA using NGF as the target and anti-equine polyclonal antibody-horseradish peroxidase secondary reagent. The plasma concentrations measured are consistent with two-phase kinetics, with a tissue distribution (alpha) phase and an elimination phase (beta) phase of several days. The absence of a sharp decline in plasma concentration of anti-equine NGF antibody concentration between 100 and 300 hours is expected. This would demonstrate that there is neither pre-existing neutralising antibodies to recombinant anti-NGF monoclonal antibodies in horse blood nor are any such neutralising antibodies generated following infusion.
Example 9
Anti-Equine NGF Monoclonal Antibodies Reduce Inflammatory Pain Due to Osteoarthritis In Vivo
[0174] Groups of osteoarthritic horses are injected intravenously or intra-articularly with either anti-equine NGF monoclonal antibodies of this patent at 0.01-10 mg/kg body weight or phosphate buffered saline as vehicle control (=day 0). The horses are assessed for lameness over 4-14 days by a visual scoring method (e.g. score 0, no lameness (full weight bearing); score 1, slight lameness (not full weight bearing but walking well); score 2, moderate lameness (slightly weight bearing and not walking well), score 3, severe lameness (not weight bearing)). Observers are blinded to which horses receive which injection.
[0175] Lameness scores are expected to be reduced in the horses receiving anti-equine NGF monoclonal antibodies over time post-injection compared with vehicle control, indicating that the anti-equine NGF monoclonal antibodies will have an effect in reducing the pain in the horses over that seen with vehicle alone.
Example 10
Comparison Example Showing the Effect of Anti-Canine NGF Monoclonal Antibodies in Reducing Inflammatory Pain In Vivo
Antibody Therapy:
[0176] The method of preparing antibodies of the present invention was applied to produce a caninised antibody suitable for use in canines. A caninised aD11 VL domain was combined with a canine kappa light chain constant domain and a caninised aD11 VH domain was combined with a canine heavy chain isotype. Anti-canine NGF monoclonal antibodies derived from expression vectors expressing the heavy and light chains were expressed in CHO cells and purified by a combination of ion exchange chromatography, hydrophobic interaction chromatography and size exclusion chromatography and buffer exchanged into phosphate buffered saline.
Canine Model of Inflammation:
[0177] All experiments were carried out with prior approval of the Institutional Ethics Committee (CRL, Ireland). Beagle dogs were injected (=day-1) with kaolin into the footpad of one hind leg in order to generate a self-resolving inflammation beginning approximately 24 hours later and which causes the dogs to become temporarily lame. In this model, once the initial inflammation response to kaolin recedes, the dogs become steadily less lame over the period of approximately 1-2 weeks and then make a full recovery. Groups of 3 dogs were injected intravenously with either anti-canine NGF monoclonal antibodies at 200 g/kg body weight or phosphate buffered saline as vehicle control (=day 0). The dogs were assessed for lameness over 7 days by a visual scoring method (score 0, no lameness (full weight bearing); score 1, slight lameness (not full weight bearing but walking well); score 2, moderate lameness (slightly weight bearing and not walking well), score 3, severe lameness (not weight bearing)). Observers were blinded to which dogs received which injection. The results are shown in
[0178] All documents referred to in this specification are herein incorporated by reference. Various modifications and variations to the described embodiments of the inventions will be apparent to those skilled in the art without departing from the scope of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes of carrying out the invention which are obvious to those skilled in the art are intended to be covered by the present invention.